[{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"548aa500-8c12-4f07-a648-778d8d4336f5","acronym":"TOMAS2","url":"https://clinicaltrials.gov/study/NCT03838744","created_at":"2021-01-18T18:56:57.653Z","updated_at":"2025-02-25T15:08:19.930Z","phase":"Phase 2","brief_title":"Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.","source_id_and_acronym":"NCT03838744 - TOMAS2","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-12-04"},{"id":"979632e5-5844-47cd-bb14-5dedd6d753fe","acronym":"TRABTRAP","url":"https://clinicaltrials.gov/study/NCT05597917","created_at":"2022-10-28T13:57:00.387Z","updated_at":"2024-07-02T16:35:25.392Z","phase":"Phase 3","brief_title":"tTF-NGR Randomized Study - STS","source_id_and_acronym":"NCT05597917 - TRABTRAP","lead_sponsor":"Universität Münster","biomarkers":" BCOR • ANPEP","pipe":"","alterations":" ","tags":["BCOR • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-22"},{"id":"73b9aa98-7882-4ef9-8648-1da0dc4ba8a9","acronym":"SARC037","url":"https://clinicaltrials.gov/study/NCT04067115","created_at":"2021-01-18T19:55:32.138Z","updated_at":"2024-07-02T16:35:25.576Z","phase":"Phase 1/2","brief_title":"SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients","source_id_and_acronym":"NCT04067115 - SARC037","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Yondelis (trabectedin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-12-21"},{"id":"f7315e28-fa58-4818-96a0-d6747f9a7418","acronym":"ISG-MCS","url":"https://clinicaltrials.gov/study/NCT04305548","created_at":"2022-03-10T21:59:21.461Z","updated_at":"2024-07-02T16:35:37.152Z","phase":"Phase 2","brief_title":"Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma","source_id_and_acronym":"NCT04305548 - ISG-MCS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" HEY1 • NCOA2","pipe":"","alterations":" ","tags":["HEY1 • NCOA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-13"},{"id":"985dbe59-edc4-40c6-b4c4-daf7da0b5372","acronym":"TRASTS","url":"https://clinicaltrials.gov/study/NCT02275286","created_at":"2022-06-01T12:55:54.963Z","updated_at":"2024-07-02T16:35:46.759Z","phase":"Phase 1/2","brief_title":"Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients","source_id_and_acronym":"NCT02275286 - TRASTS","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2023-05-31"},{"id":"a95aec49-3776-4a7a-a329-90349bf3ac75","acronym":"TRAMUNE","url":"https://clinicaltrials.gov/study/NCT03085225","created_at":"2021-01-18T15:11:58.019Z","updated_at":"2025-02-25T14:57:54.358Z","phase":"Phase 1","brief_title":"Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.","source_id_and_acronym":"NCT03085225 - TRAMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2023-03-03"},{"id":"34fb42bf-5489-4d14-b865-5d4cdb3a0b49","acronym":"NiTraSarc","url":"https://clinicaltrials.gov/study/NCT03590210","created_at":"2021-01-18T17:39:22.163Z","updated_at":"2025-02-25T14:27:17.508Z","phase":"Phase 2","brief_title":"Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas","source_id_and_acronym":"NCT03590210 - NiTraSarc","lead_sponsor":"University Medicine Greifswald","biomarkers":" PD-L1 • CTLA4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 02/12/2022","primary_completion_date":" 02/12/2022","study_txt":" Completion: 02/12/2022","study_completion_date":" 02/12/2022","last_update_posted":"2022-11-08"},{"id":"c51e6e50-5085-47cf-93de-3705060c59fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03470805","created_at":"2021-01-18T17:06:19.180Z","updated_at":"2025-02-25T14:58:47.292Z","phase":"Phase 2","brief_title":"Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma","source_id_and_acronym":"NCT03470805","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • pegylated liposomal doxorubicin • Yondelis (trabectedin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 07/27/2022","primary_completion_date":" 07/27/2022","study_txt":" Completion: 07/27/2022","study_completion_date":" 07/27/2022","last_update_posted":"2022-09-23"},{"id":"79ba1568-d944-4f02-8f3a-52d7c5e73775","acronym":"TvsCH","url":"https://clinicaltrials.gov/study/NCT05512676","created_at":"2022-08-23T14:55:39.488Z","updated_at":"2024-07-02T16:36:05.041Z","phase":"","brief_title":"Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum","source_id_and_acronym":"NCT05512676 - TvsCH","lead_sponsor":"Oslo University Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pegylated liposomal doxorubicin • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 05/20/2019","primary_completion_date":" 05/20/2019","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2022-08-23"},{"id":"ae77e194-ff53-4dfc-845b-4d87595d81c6","acronym":"NIMES-ROC","url":"https://clinicaltrials.gov/study/NCT02825420","created_at":"2021-10-29T19:53:55.831Z","updated_at":"2024-07-02T16:36:22.169Z","phase":"","brief_title":"Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients","source_id_and_acronym":"NCT02825420 - NIMES-ROC","lead_sponsor":"PharmaMar","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 220","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 09/18/2019","study_completion_date":" 09/18/2019","last_update_posted":"2021-10-29"},{"id":"5b155166-456e-4e98-ab35-93aa83881242","acronym":"Mito23","url":"https://clinicaltrials.gov/study/NCT02903004","created_at":"2021-01-18T14:14:50.207Z","updated_at":"2024-07-02T16:36:25.860Z","phase":"Phase 3","brief_title":"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients","source_id_and_acronym":"NCT02903004 - Mito23","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Yondelis (trabectedin) • topotecan • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 242","initiation":"Initiation: 04/11/2016","start_date":" 04/11/2016","primary_txt":" Primary completion: 12/20/2018","primary_completion_date":" 12/20/2018","study_txt":" Completion: 12/20/2018","study_completion_date":" 12/20/2018","last_update_posted":"2021-08-25"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"},{"id":"10270926-5ac6-4697-bea9-2ffc0991ea57","acronym":"ATREUS","url":"https://clinicaltrials.gov/study/NCT02194231","created_at":"2021-01-18T10:14:55.957Z","updated_at":"2024-07-02T16:36:50.984Z","phase":"Phase 2","brief_title":"ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)","source_id_and_acronym":"NCT02194231 - ATREUS","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HMGB1","pipe":"","alterations":" ","tags":["HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin) • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 12/12/2019","study_completion_date":" 12/12/2019","last_update_posted":"2020-01-23"},{"id":"26365345-1570-49ca-8578-b67aa79e6819","acronym":"","url":"https://clinicaltrials.gov/study/NCT03397186","created_at":"2021-01-18T16:45:56.830Z","updated_at":"2024-07-02T16:36:55.814Z","phase":"Phase 2","brief_title":"Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma","source_id_and_acronym":"NCT03397186","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3","pipe":" | ","alterations":" CCR5 expression","tags":["CD8 • LAG3 • CTLA4 • CD4 • CCR5 • CXCR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCR5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 05/01/2021","study_completion_date":" 05/01/2021","last_update_posted":"2019-09-10"},{"id":"361e21ce-7b50-4730-97db-b33c50da6aa6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01846611","created_at":"2021-01-17T17:37:39.191Z","updated_at":"2024-07-02T16:37:01.063Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT01846611","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Yondelis (trabectedin) • dexamethasone • dexamethasone injection • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 581","initiation":"Initiation: 10/16/2013","start_date":" 10/16/2013","primary_txt":" Primary completion: 01/18/2018","primary_completion_date":" 01/18/2018","study_txt":" Completion: 11/16/2018","study_completion_date":" 11/16/2018","last_update_posted":"2019-04-01"}]